Reports Q4 revenue $0, consensus $50,000. “Our clinical and corporate execution in 2018 places UroGen in a position of strength as we prepare to potentially deliver UGN-101 as the first approved therapy for patients with low-grade upper tract urothelial cancer,” said Liz Barrett, President and CEO of UroGen. “With this solid foundation, we remain intensely focused on finalizing our rolling New Drug Application and accelerating commercial preparation to ensure a successful launch upon approval with seamless adoption of UGN-101. We believe UGN-101 is just the beginning of what may be possible with our proprietary RTGel technology platform.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.